GCG and type 2 diabetes mellitus: Lixisenatide has demonstrated dose-dependent improvements in post-meal glucose levels and suppression of postprandial glucagon secretion in patients with type 2 diabetes insufficiently controlled with metformin, as well as pharmacodynamic effects consistent with a glucose-dependent effect on insulin secretion and suggested improvements in ß-cell function [12].